Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 734

1.

Valproate and Retinoic Acid in Combination With Decitabine in Elderly Nonfit Patients With Acute Myeloid Leukemia: Results of a Multicenter, Randomized, 2 × 2, Phase II Trial.

Lübbert M, Grishina O, Schmoor C, Schlenk RF, Jost E, Crysandt M, Heuser M, Thol F, Salih HR, Schittenhelm MM, Germing U, Kuendgen A, Götze KS, Lindemann HW, Müller-Tidow C, Heil G, Scholl S, Bug G, Schwaenen C, Giagounidis A, Neubauer A, Krauter J, Brugger W, De Wit M, Wäsch R, Becker H, May AM, Duyster J, Döhner K, Ganser A, Hackanson B, Döhner H; DECIDER Study Team.

J Clin Oncol. 2019 Dec 3:JCO1901053. doi: 10.1200/JCO.19.01053. [Epub ahead of print]

PMID:
31794324
2.

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients with Therapy-Related Myeloid Neoplasm: A Study from the Chronic Malignancies Working Party of the EBMT.

Robin M, Wang J, Koster L, Beelen DW, Bornhäuser M, Kroeger N, Platzbecker U, Finke J, Ganser A, Blaise D, Ciceri F, Maertens J, Labussiere-Wallet H, Chevallier P, Passweg JR, Cornelissen JJ, Milpied N, Charbonnier A, Bonifazi F, de Wreede LC, Hayden P, Scheid C, Yakoub-Agha I.

Blood. 2019 Nov 13;134(Supplement_1):45. doi: 10.1182/blood-2019-124765.

PMID:
31724025
3.

Autologous hematopoietic stem cell transplantation for relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the lymphoma working party (LWP) of the EBMT.

Domingo-Domènech E, Boumendil A, Climent F, Sengeloev H, Wahlin B, Wattad W, Arat M, Finel H, Schapp N, Ganser A, Yeshurun M, Pavone V, Snowden J, Finke J, Montoto S, Sureda A, Dreger P; Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.

Bone Marrow Transplant. 2019 Nov 6. doi: 10.1038/s41409-019-0734-7. [Epub ahead of print]

PMID:
31695174
4.

FLA-IDA salvage chemotherapy combined with a seven-day course of venetoclax (FLAVIDA) in patients with relapsed/refractory acute leukaemia.

Shahswar R, Beutel G, Klement P, Rehberg A, Gabdoulline R, Koenecke C, Markel D, Eggers H, Eder M, Stadler M, Hambach L, Ehrlich S, Göhring G, Schlegelberger B, Dammann E, Reuter M, Wichmann M, Neziri B, Ganser A, Thol F, Heuser M.

Br J Haematol. 2019 Nov 4. doi: 10.1111/bjh.16268. [Epub ahead of print] No abstract available.

PMID:
31681986
5.

Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.

Carré M, Porcher R, Finke J, Ehninger G, Koster L, Beelen D, Ganser A, Volin L, Lozano S, Friis L, Michallet M, Tischer J, Olavarria E, Cascon MJP, Iacobelli S, Koc Y, Jindra P, Arat M, de Witte T, Yakoub Agha I, Kröger N, Robin M.

Biol Blood Marrow Transplant. 2019 Oct 21. pii: S1083-8791(19)30672-X. doi: 10.1016/j.bbmt.2019.10.015. [Epub ahead of print]

PMID:
31647984
6.

Monocytes reprogrammed with lentiviral vectors co-expressing GM-CSF, IFN-α2 and antigens for personalized immune therapy of acute leukemia pre- or post-stem cell transplantation.

Bialek-Waldmann JK, Heuser M, Ganser A, Stripecke R.

Cancer Immunol Immunother. 2019 Nov;68(11):1891-1899. doi: 10.1007/s00262-019-02406-9. Epub 2019 Oct 18. Review.

7.

Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial.

Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts CH, Hanel M, Rollig C, Schmitz N, Link H, Frairia C, Fozza C, Maria D'Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Voso MT, Ehninger G, Schlenk RF, Lo-Coco F.

Leukemia. 2019 Oct 14. doi: 10.1038/s41375-019-0589-3. [Epub ahead of print] No abstract available.

PMID:
31611624
8.

Association of uric acid levels before start of conditioning with mortality after alloSCT: a prospective, non-interventional study of the EBMT Transplant Complication Working Party.

Penack O, Peczynski C, van der Werf S, Finke J, Ganser A, Schoemans H, Pavlu J, Niittyvuopio R, Schroyens W, Kaynar L, Blau IW, van der Velden W, Sierra J, Cortelezzi A, Wulf G, Turlure P, Rovira M, Ozkurt Z, Pascual-Cascon MJ, Moreira MC, Clausen J, Greinix H, Duarte RF, Basak GW.

Haematologica. 2019 Oct 10. pii: haematol.2019.228668. doi: 10.3324/haematol.2019.228668. [Epub ahead of print]

9.

In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site.

Chaturvedi A, Goparaju R, Gupta C, Weder J, Klünemann T, Araujo Cruz MM, Kloos A, Goerlich K, Schottmann R, Othman B, Struys EA, Bähre H, Grote-Koska D, Brand K, Ganser A, Preller M, Heuser M.

Leukemia. 2019 Oct 4. doi: 10.1038/s41375-019-0582-x. [Epub ahead of print]

PMID:
31586149
10.

Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group.

Rücker FG, Agrawal M, Corbacioglu A, Weber D, Kapp-Schwoerer S, Gaidzik VI, Jahn N, Schroeder T, Wattad M, Lübbert M, Koller E, Kindler T, Götze K, Ringhoffer M, Westermann J, Fiedler W, Horst HA, Greil R, Schroers R, Mayer K, Heinicke T, Krauter J, Schlenk RF, Thol F, Heuser M, Ganser A, Bullinger L, Paschka P, Döhner H, Döhner K.

Blood. 2019 Nov 7;134(19):1608-1618. doi: 10.1182/blood.2019001425.

PMID:
31554635
11.

Transplant outcomes for patients with therapy-related acute myeloid leukemia with prior lymphoid malignancy: an ALWP of EBMT study.

Gatwood KS, Labopin M, Savani BN, Finke J, Socie G, Beelen D, Yakoub-Agha I, Chevallier P, Ganser A, Blaise D, Milpied N, Bruno L, Mailhol A, Mohty M, Nagler A.

Bone Marrow Transplant. 2019 Sep 16. doi: 10.1038/s41409-019-0673-3. [Epub ahead of print]

PMID:
31527819
12.

Functional and clinical characterization of the alternatively spliced isoform AML1-ETO9a in adult patients with translocation t(8;21)(q22;q22.1) acute myeloid leukemia (AML).

Agrawal M, Schwarz P, Giaimo BD, Bedzhov I, Corbacioglu A, Weber D, Gaidzik VI, Jahn N, Rücker FG, Schroeder T, Kindler T, Wattad M, Götze K, Lübbert M, Salwender H, Ringhoffer M, Lange E, Koller E, Thol F, Heuser M, Ganser A, Bullinger L, Paschka P, Döhner H, Geiger H, Borggrefe T, Döhner K, Oswald F.

Leukemia. 2019 Aug 28. doi: 10.1038/s41375-019-0551-4. [Epub ahead of print] No abstract available.

PMID:
31462736
13.

MN1 is indispensable for MLL-rearranged acute myeloid leukemia.

Sharma A, Jyotsana N, Gabdoulline R, Heckl D, Kuchenbauer F, Slany RK, Ganser A, Heuser M.

Haematologica. 2019 Aug 14. pii: haematol.2018.211201. doi: 10.3324/haematol.2018.211201. [Epub ahead of print]

14.

Adenosine stress perfusion cardiac magnetic resonance imaging in patients undergoing intracoronary bone marrow cell transfer after ST-elevation myocardial infarction: the BOOST-2 perfusion substudy.

Seitz A, Wollert KC, Meyer GP, Müller-Ehmsen J, Tschöpe C, May AE, Empen K, Chorianopoulos E, Ritter B, Pirr J, Arseniev L, Heuft HG, Ganser A, Abu-Zaid E, Katus HA, Felix SB, Gawaz MP, Schultheiss HP, Ladage D, Bauersachs J, Mahrholdt H, Greulich S.

Clin Res Cardiol. 2019 Aug 10. doi: 10.1007/s00392-019-01537-4. [Epub ahead of print]

PMID:
31401672
15.

Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia.

Lucena-Araujo AR, Coelho-Silva JL, Pereira-Martins DA, Silveira DR, Koury LC, Melo RAM, Bittencourt R, Pagnano K, Pasquini R, Nunes EC, Fagundes EM, Gloria AB, Kerbauy F, de Lourdes Chauffaille M, Bendit I, Rocha V, Keating A, Tallman MS, Ribeiro RC, Dillon R, Ganser A, Löwenberg B, Valk PJM, Lo-Coco F, Sanz MA, Berliner N, Rego EM.

Blood. 2019 Sep 19;134(12):951-959. doi: 10.1182/blood.2019000239. Epub 2019 Jul 10.

PMID:
31292112
16.

Comparable Long-Term Outcome after Allogeneic Stem Cell Transplantation from Sibling and Matched Unrelated Donors in Patients with Acute Myeloid Leukemia Older Than 50 Years: A Report on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Shimoni A, Labopin M, Savani B, Byrne M, Volin L, Finke J, Niederwieser D, Ehninger G, Blaise D, Beelen D, Tabrizi R, Sengeloev H, Ganser A, Cornelissen JJ, Mohty M, Nagler A.

Biol Blood Marrow Transplant. 2019 Nov;25(11):2251-2260. doi: 10.1016/j.bbmt.2019.06.031. Epub 2019 Jul 2.

PMID:
31271887
17.

Posttransplant cyclophosphamide vs antithymocyte globulin in HLA-mismatched unrelated donor transplantation.

Battipaglia G, Labopin M, Kröger N, Vitek A, Afanasyev B, Hilgendorf I, Schetelig J, Ganser A, Blaise D, Itälä-Remes M, Passweg JR, Bonifazi F, Finke J, Ruggeri A, Nagler A, Mohty M.

Blood. 2019 Sep 12;134(11):892-899. doi: 10.1182/blood.2019000487. Epub 2019 Jul 3.

PMID:
31270102
18.

Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Age >69 Years with Acute Myelogenous Leukemia: On Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Ringdén O, Boumendil A, Labopin M, Canaani J, Beelen D, Ehninger G, Niederwieser D, Finke J, Stelljes M, Gerbitz A, Ganser A, Kröger N, Kantz L, Brecht A, Savani B, Sadeghi B, Mohty M, Nagler A.

Biol Blood Marrow Transplant. 2019 Oct;25(10):1975-1983. doi: 10.1016/j.bbmt.2019.05.037. Epub 2019 Jun 7.

PMID:
31181255
19.

Lipid nanoparticle-mediated siRNA delivery for safe targeting of human CML in vivo.

Jyotsana N, Sharma A, Chaturvedi A, Budida R, Scherr M, Kuchenbauer F, Lindner R, Noyan F, Sühs KW, Stangel M, Grote-Koska D, Brand K, Vornlocher HP, Eder M, Thol F, Ganser A, Humphries RK, Ramsay E, Cullis P, Heuser M.

Ann Hematol. 2019 Aug;98(8):1905-1918. doi: 10.1007/s00277-019-03713-y. Epub 2019 May 18.

PMID:
31104089
20.

Clonal evolution patterns in acute myeloid leukemia with NPM1 mutation.

Cocciardi S, Dolnik A, Kapp-Schwoerer S, Rücker FG, Lux S, Blätte TJ, Skambraks S, Krönke J, Heidel FH, Schnöder TM, Corbacioglu A, Gaidzik VI, Paschka P, Teleanu V, Göhring G, Thol F, Heuser M, Ganser A, Weber D, Sträng E, Kestler HA, Döhner H, Bullinger L, Döhner K.

Nat Commun. 2019 May 2;10(1):2031. doi: 10.1038/s41467-019-09745-2.

21.

Allogeneic stem cell transplantation using HLA-matched donors for acute myeloid leukemia with deletion 5q or monosomy 5: a study from the Acute Leukemia Working Party of the EBMT.

Poiré X, Labopin M, Polge E, Forcade E, Ganser A, Volin L, Michallet M, Blaise D, Yakoub-Agha I, Maertens J, Richard Espiga C, Cornelissen J, Finke J, Mohty M, Esteve J, Nagler A; Acute Leukemia Working Party of the EBMT.

Haematologica. 2019 May 2. pii: haematol.2019.216168. doi: 10.3324/haematol.2019.216168. [Epub ahead of print]

22.

Focusing of the regulatory T-cell repertoire after allogeneic stem cell transplantation indicates protection from graft-versus-host disease.

Odak I, Raha S, Schultze-Florey C, Tavil S, Ravens S, Ganser A, Förster R, Prinz I, Koenecke C.

Haematologica. 2019 Dec;104(12):e577-e580. doi: 10.3324/haematol.2019.218206. Epub 2019 Apr 24. No abstract available.

23.

Umbilical cord blood versus unrelated donor transplantation in adults with primary refractory or relapsed acute myeloid leukemia: a report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy and Immunobiology Working Party of the EBMT.

Baron F, Labopin M, Ruggeri A, Ehninger G, Bonifazi F, Stelljes M, Sanz J, Stuhler G, Bosi A, Kröger N, Van Lint MT, Ganser A, Forcade E, Mohty M, Gluckman E, Nagler A.

Blood Cancer J. 2019 Apr 12;9(4):46. doi: 10.1038/s41408-019-0204-x.

24.

Cytomegalovirus-specific CD8+ T-cells are associated with a reduced incidence of early relapse after allogeneic stem cell transplantation.

Varanasi PR, Ogonek J, Luther S, Dammann E, Stadler M, Ganser A, Borchers S, Hambach L, Weissinger EM.

PLoS One. 2019 Mar 19;14(3):e0213739. doi: 10.1371/journal.pone.0213739. eCollection 2019.

25.

Randomized phase-II trial evaluating induction therapy with idarubicin and etoposide plus sequential or concurrent azacitidine and maintenance therapy with azacitidine.

Schlenk RF, Weber D, Herr W, Wulf G, Salih HR, Derigs HG, Kuendgen A, Ringhoffer M, Hertenstein B, Martens UM, Grießhammer M, Bernhard H, Krauter J, Girschikofsky M, Wolf D, Lange E, Westermann J, Koller E, Kremers S, Wattad M, Heuser M, Thol F, Göhring G, Haase D, Teleanu V, Gaidzik V, Benner A, Döhner K, Ganser A, Paschka P, Döhner H.

Leukemia. 2019 Aug;33(8):1923-1933. doi: 10.1038/s41375-019-0395-y. Epub 2019 Feb 6.

26.

Six versus eight doses of rituximab in patients with aggressive B cell lymphoma receiving six cycles of CHOP: results from the "Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas" (PETAL) trial.

Hüttmann A, Rekowski J, Müller SP, Hertenstein B, Franzius C, Mesters R, Weckesser M, Kroschinsky F, Kotzerke J, Ganser A, Bengel FM, La Rosée P, Freesmeyer M, Höffkes HG, Hertel A, Behringer D, Prange-Krex G, Griesshammer M, Holzinger J, Wilop S, Krohn T, Raghavachar A, Maschmeyer G, Brink I, Schroers R, Gaska T, Bernhard H, Giagounidis A, Schütte J, Dienst A, Hautzel H, Naumann R, Klein A, Hahn D, Pöpperl G, Grube M, Marienhagen J, Schwarzer A, Kurch L, Höhler T, Steiniger H, Nückel H, Südhoff T, Römer W, Brinkmann M, Ose C, Alashkar F, Schmitz C, Dürig J, Hoelzer D, Jöckel KH, Klapper W, Dührsen U.

Ann Hematol. 2019 Apr;98(4):897-907. doi: 10.1007/s00277-018-3578-0. Epub 2019 Jan 4.

PMID:
30610279
27.

Genomic landscape and clonal evolution of acute myeloid leukemia with t(8;21): an international study on 331 patients.

Christen F, Hoyer K, Yoshida K, Hou HA, Waldhueter N, Heuser M, Hills RK, Chan W, Hablesreiter R, Blau O, Ochi Y, Klement P, Chou WC, Blau IW, Tang JL, Zemojtel T, Shiraishi Y, Shiozawa Y, Thol F, Ganser A, Löwenberg B, Linch DC, Bullinger L, Valk PJM, Tien HF, Gale RE, Ogawa S, Damm F.

Blood. 2019 Mar 7;133(10):1140-1151. doi: 10.1182/blood-2018-05-852822. Epub 2019 Jan 4.

PMID:
30610028
28.

Comparative outcomes of myeloablative and reduced-intensity conditioning allogeneic hematopoietic cell transplantation for therapy-related acute myeloid leukemia with prior solid tumor: A report from the acute leukemia working party of the European society for blood and bone marrow transplantation.

Lee CJ, Labopin M, Beelen D, Finke J, Blaise D, Ganser A, Itälä-Remes M, Chevallier P, Labussière-Wallet H, Maertens J, Yakoub-Agha I, Bourhis JH, Mailhol A, Mohty M, Savani BN, Nagler A.

Am J Hematol. 2019 Apr;94(4):431-438. doi: 10.1002/ajh.25395. Epub 2019 Jan 10.

PMID:
30597620
29.

Spatiotemporally Skewed Activation of Programmed Cell Death Receptor 1-Positive T Cells after Epstein-Barr Virus Infection and Tumor Development in Long-Term Fully Humanized Mice.

Danisch S, Slabik C, Cornelius A, Albanese M, Tagawa T, Chen YA, Krönke N, Eiz-Vesper B, Lienenklaus S, Bleich A, Theobald SJ, Schneider A, Ganser A, von Kaisenberg C, Zeidler R, Hammerschmidt W, Feuerhake F, Stripecke R.

Am J Pathol. 2019 Mar;189(3):521-539. doi: 10.1016/j.ajpath.2018.11.014. Epub 2018 Dec 26.

30.

Late treatment-related mortality versus competing causes of death after allogeneic transplantation for myelodysplastic syndromes and secondary acute myeloid leukemia.

Schetelig J, de Wreede LC, van Gelder M, Koster L, Finke J, Niederwieser D, Beelen D, Mufti GJ, Platzbecker U, Ganser A, Heidenreich S, Maertens J, Socié G, Brecht A, Stelljes M, Kobbe G, Volin L, Nagler A, Vitek A, Luft T, Ljungman P, Yakoub-Agha I, Robin M, Kröger N.

Leukemia. 2019 Mar;33(3):686-695. doi: 10.1038/s41375-018-0302-y. Epub 2018 Dec 20.

31.

Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD.

Schlenk RF, Weber D, Fiedler W, Salih HR, Wulf G, Salwender H, Schroeder T, Kindler T, Lübbert M, Wolf D, Westermann J, Kraemer D, Götze KS, Horst HA, Krauter J, Girschikofsky M, Ringhoffer M, Südhoff T, Held G, Derigs HG, Schroers R, Greil R, Grießhammer M, Lange E, Burchardt A, Martens U, Hertenstein B, Marretta L, Heuser M, Thol F, Gaidzik VI, Herr W, Krzykalla J, Benner A, Döhner K, Ganser A, Paschka P, Döhner H; German-Austrian AML Study Group.

Blood. 2019 Feb 21;133(8):840-851. doi: 10.1182/blood-2018-08-869453. Epub 2018 Dec 18.

PMID:
30563875
32.

Optimized induction of mitochondrial apoptosis for chemotherapy-free treatment of BCR-ABL+acute lymphoblastic leukemia.

Scherr M, Kirchhoff H, Battmer K, Wohlan K, Lee CW, Ricke-Hoch M, Erschow S, Law E, Kloos A, Heuser M, Ganser A, Hilfiker-Kleiner D, Heidenreich O, Eder M.

Leukemia. 2019 Jun;33(6):1313-1323. doi: 10.1038/s41375-018-0315-6. Epub 2018 Dec 13.

33.

Signatures of T and B Cell Development, Functional Responses and PD-1 Upregulation After HCMV Latent Infections and Reactivations in Nod.Rag.Gamma Mice Humanized With Cord Blood CD34+ Cells.

Theobald SJ, Khailaie S, Meyer-Hermann M, Volk V, Olbrich H, Danisch S, Gerasch L, Schneider A, Sinzger C, Schaudien D, Lienenklaus S, Riese P, Guzman CA, Figueiredo C, von Kaisenberg C, Spineli LM, Glaesener S, Meyer-Bahlburg A, Ganser A, Schmitt M, Mach M, Messerle M, Stripecke R.

Front Immunol. 2018 Nov 22;9:2734. doi: 10.3389/fimmu.2018.02734. eCollection 2018.

34.

Phase I/II study on cytarabine and idarubicin combined with escalating doses of clofarabine in newly diagnosed patients with acute myeloid leukaemia and high risk for induction failure (AMLSG 17-10 CIARA trial).

Krauter J, Fiedler W, Schlenk RF, Paschka P, Thol F, Lübbert M, Wattad M, Verbeek M, Könecke C, Neuhaus B, Papkalla A, Kebenko M, Janning M, Döhner K, Gaidzik VI, Becker H, Greil C, Reimer P, Götze KS, Döhner H, Ganser A, Heuser M.

Br J Haematol. 2018 Oct;183(2):235-241. doi: 10.1111/bjh.15546.

PMID:
30378121
35.

Haploidentical versus unrelated allogeneic stem cell transplantation for relapsed/refractory acute myeloid leukemia: a report on 1578 patients from the Acute Leukemia Working Party of the EBMT.

Brissot E, Labopin M, Ehninger G, Stelljes M, Brecht A, Ganser A, Tischer J, Kröger N, Afanasyev B, Finke J, Elmaagacli A, Einsele H, Mohty M, Nagler A.

Haematologica. 2019 Mar;104(3):524-532. doi: 10.3324/haematol.2017.187450. Epub 2018 Oct 25.

36.

Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion.

Feurstein S, Thomay K, Hofmann W, Buesche G, Kreipe H, Thol F, Heuser M, Ganser A, Schlegelberger B, Göhring G.

Int J Mol Sci. 2018 Oct 21;19(10). pii: E3269. doi: 10.3390/ijms19103269.

37.

Cumulative dosages of chemotherapy and radiotherapy exposure, and risk of secondary malignancies after allogeneic hematopoietic stem cell transplantation.

Ziegler AK, Abend M, Port M, Dammann E, Homeyer RS, Eder M, Ganser A, Schrem H, Koenecke C.

Bone Marrow Transplant. 2019 Apr;54(4):635-640. doi: 10.1038/s41409-018-0359-2. Epub 2018 Oct 18. No abstract available.

PMID:
30337701
38.

miR-125b regulates chemotaxis and survival of bone marrow derived granulocytes in vitro and in vivo.

Lee CW, Schoenherr C, Battmer K, Ganser A, Hilfiker-Kleiner D, David S, Eder M, Scherr M.

PLoS One. 2018 Oct 4;13(10):e0204942. doi: 10.1371/journal.pone.0204942. eCollection 2018.

39.

Measurable residual disease monitoring by NGS before allogeneic hematopoietic cell transplantation in AML.

Thol F, Gabdoulline R, Liebich A, Klement P, Schiller J, Kandziora C, Hambach L, Stadler M, Koenecke C, Flintrop M, Pankratz M, Wichmann M, Neziri B, Büttner K, Heida B, Klesse S, Chaturvedi A, Kloos A, Göhring G, Schlegelberger B, Gaidzik VI, Bullinger L, Fiedler W, Heim A, Hamwi I, Eder M, Krauter J, Schlenk RF, Paschka P, Döhner K, Döhner H, Ganser A, Heuser M.

Blood. 2018 Oct 18;132(16):1703-1713. doi: 10.1182/blood-2018-02-829911. Epub 2018 Sep 6.

PMID:
30190321
40.

Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study.

Sengsayadeth S, Gatwood KS, Boumendil A, Labopin M, Finke J, Ganser A, Stelljes M, Ehninger G, Beelen D, Niederwieser D, Blaise D, Dreger P, Mufti G, Chevallier P, Mailhol A, Gilleece MH, Gorin N, Esteve J, Ciceri F, Baron F, Schmid C, Giebel S, Mohty M, Savani BN, Nagler A.

Blood Adv. 2018 Aug 28;2(16):2127-2135. doi: 10.1182/bloodadvances.2018019976.

41.

Improved short- and long-term outcome of allogeneic stem cell recipients admitted to the intensive care unit: a retrospective longitudinal analysis of 942 patients.

Lueck C, Stadler M, Koenecke C, Hoeper MM, Dammann E, Schneider A, Kielstein JT, Ganser A, Eder M, Beutel G.

Intensive Care Med. 2018 Sep;44(9):1483-1492. doi: 10.1007/s00134-018-5347-x. Epub 2018 Aug 23.

PMID:
30141173
42.

Comparison of FLAMSA-based reduced intensity conditioning with treosulfan/fludarabine conditioning for patients with acute myeloid leukemia: an ALWP/EBMT analysis.

Sheth V, Labopin M, Canaani J, Volin L, Brecht A, Ganser A, Mayer J, Labussière-Wallet H, Bittenbring J, Shouval R, Savani B, Mohty M, Nagler A.

Bone Marrow Transplant. 2019 Apr;54(4):531-539. doi: 10.1038/s41409-018-0288-0. Epub 2018 Aug 7.

PMID:
30087463
43.

Fast quantitative optical detection of heat dissipation by surface plasmon polaritons.

Möller TB, Ganser A, Kratt M, Dickreuter S, Waitz R, Scheer E, Boneberg J, Leiderer P.

Nanoscale. 2018 Jul 5;10(25):11894-11900. doi: 10.1039/c8nr02489h.

PMID:
29897094
44.

Adding dasatinib to intensive treatment in core-binding factor acute myeloid leukemia-results of the AMLSG 11-08 trial.

Paschka P, Schlenk RF, Weber D, Benner A, Bullinger L, Heuser M, Gaidzik VI, Thol F, Agrawal M, Teleanu V, Lübbert M, Fiedler W, Radsak M, Krauter J, Horst HA, Greil R, Mayer K, Kündgen A, Martens U, Heil G, Salih HR, Hertenstein B, Schwänen C, Wulf G, Lange E, Pfreundschuh M, Ringhoffer M, Girschikofsky M, Heinicke T, Kraemer D, Göhring G, Ganser A, Döhner K, Döhner H.

Leukemia. 2018 Jul;32(7):1621-1630. doi: 10.1038/s41375-018-0129-6. Epub 2018 Apr 17.

PMID:
29720733
45.

Diagnostic value of highly-sensitive chimerism analysis after allogeneic stem cell transplantation.

Sellmann L, Rabe K, Bünting I, Dammann E, Göhring G, Ganser A, Stadler M, Weissinger EM, Hambach L.

Bone Marrow Transplant. 2018 Nov;53(11):1457-1465. doi: 10.1038/s41409-018-0176-7. Epub 2018 May 2.

PMID:
29720704
46.

From the black Atlantic to the bleak Pacific: Re-reading "Benito Cereno".

Ganser A.

Atl Stud (Abingdon). 2018 Mar 13;15(2):218-237. doi: 10.1080/14788810.2017.1384612. eCollection 2018.

47.

Transplant Outcomes for Secondary Acute Myeloid Leukemia: Acute Leukemia Working Party of the European Society for Blood and Bone Marrow Transplantation Study.

Sengsayadeth S, Labopin M, Boumendil A, Finke J, Ganser A, Stelljes M, Ehninger G, Beelen D, Niederwieser D, Blaise D, Dreger P, Mufti G, Chevallier P, Mailhol A, Gatwood KS, Gorin N, Esteve J, Ciceri F, Baron F, Schmid C, Giebel S, Mohty M, Savani BN, Nagler A.

Biol Blood Marrow Transplant. 2018 Jul;24(7):1406-1414. doi: 10.1016/j.bbmt.2018.04.008. Epub 2018 Apr 17.

48.

Publisher Correction: Human γδ T cells are quickly reconstituted after stem-cell transplantation and show adaptive clonal expansion in response to viral infection.

Ravens S, Schultze-Florey C, Raha S, Sandrock I, Drenker M, Oberdörfer L, Reinhardt A, Ravens I, Beck M, Geffers R, von Kaisenberg C, Heuser M, Thol F, Ganser A, Förster R, Koenecke C, Prinz I.

Nat Immunol. 2018 Sep;19(9):1037. doi: 10.1038/s41590-018-0054-x.

PMID:
29449629
49.

Acquired long QT syndrome during conditioning for allogeneic stem cell transplantation-are we aware of this side effect?

Zauner F, Tayeb S, Panagiota V, Rababah M, Ganser A, Eder M, Veltmann C, Beutel G.

Ann Hematol. 2018 Jun;97(6):1111-1113. doi: 10.1007/s00277-018-3262-4. Epub 2018 Feb 9. No abstract available.

PMID:
29427187
50.

Flow cytometric characterization of acute leukemia reveals a distinctive "blast gate" of murine T-lymphoblastic leukemia/lymphoma.

Pan Z, Yang M, Huang K, Büsche G, Glage S, Ganser A, Li Z.

Oncotarget. 2017 Dec 18;9(2):2320-2328. doi: 10.18632/oncotarget.23410. eCollection 2018 Jan 5.

Supplemental Content

Loading ...
Support Center